Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), …
CEPHEUS Trial Results: Daratumumab-VRd in Transplant-Ineligible …
Dec 3, 2024 · Saad Z. Usmani, MD, MBA, FACP, FASCO, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, discusses the results and potential impact from the …
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing …
Key Advances in Oncology: Top Highlights From ESMO 2024
Sep 18, 2024 · This year's 2024 ESMO Congress brought forth a wave of groundbreaking developments poised to shape the future of oncology. As an essential platform for sharing …
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab …
IMforte Shows Benefits of Lurbinectedin/Atezolizumab in ES-SCLC
Oct 15, 2024 · Lurbinectedin (Zepzelca) plus the PD-L1 inhibitor atezolizumab (Tecentriq) led to positive topline results in the phase 3 IMforte study (NCT05091567) vs atezolizumab alone …
FDA Approves Zanidatamab in HER2+ Biliary Tract Cancer
Nov 21, 2024 · The FDA granted an accelerated approval to zanidatamab-hrii (Ziihera) for the treatment of patients with previously treated, unresectable or metastatic HER2-positive …
Does Odronextamab Show Hope in FL and DLBCL Despite …
Nov 5, 2024 · “This study yielded some very good overall response rates of 80%, and mostly complete response rates. Those responses were durable, with a median duration of response …
FDA Issues Warning on BioZorb Markers After Recall Due to …
Oct 30, 2024 · The FDA has warned against using BioZorb Markers due to potential adverse effects (AEs), following Hologic’s recall of all unused devices. Patients report pain, infection, …
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in …
Sep 16, 2024 · In patients with HER2- and hormone receptor (HR)-positive metastatic breast cancer, chemotherapy-free treatment with dual HER2-targeted therapy, consisting of …